Drugs /

modified folfox6 regimen

Back to Drugs List

Overview

NCI Definition [1]:
A chemotherapy regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin used for the treatment of advanced-stage and metastatic colorectal cancer. This modified version differs from the FOLFOX6 regimen in that the dose of oxaliplatin is lower.

Clinical Trials

View Clinical Trials for modified folfox6 regimen

Modified folfox6 regimen has been investigated in 27 clinical trials, of which 23 are open and 4 are closed. Of the trials investigating modified folfox6 regimen, 6 are phase 1 (4 open), 5 are phase 1/phase 2 (5 open), 12 are phase 2 (10 open), 2 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for modified folfox6 regimen clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and colorectal carcinoma are the most common diseases being investigated in modified folfox6 regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Modified Folfox6 Regimen
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Modified Folfox6 Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating modified folfox6 regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mfolfox-6, mfolfox-6 regimen, mfolfox6, folfox6, folfox-6
NCIT ID [1]:
C155746

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.